[PDF][PDF] Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2
Cancer cells can avoid and suppress immune responses through activation of inhibitory
immune checkpoint proteins, such as PD-1, PD-L1, and CTLA-4. Blocking the activities of …
immune checkpoint proteins, such as PD-1, PD-L1, and CTLA-4. Blocking the activities of …
Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization …
K Guzik, KM Zak, P Grudnik, K Magiera… - Journal of Medicinal …, 2017 - ACS Publications
Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has
provided significant advances in cancer treatment. The antibody-based immunotherapies …
provided significant advances in cancer treatment. The antibody-based immunotherapies …
Inhibitors of the PD1/PD-L1 interaction: missteps, mechanisms and mysteries
R Hanley - 2017 - dspace.library.uvic.ca
The interactions of tumours with normal host tissue are key determinants of cancer growth
and progression. The ability or inability of the patient's immune system to mount a response …
and progression. The ability or inability of the patient's immune system to mount a response …
Computational Design of Hyperstable, De Novo Miniproteins Targeting PD-1
CM Bryan - 2017 - digital.lib.washington.edu
Computational protein design has recently advanced to a new era with the de novo design
of stable proteins targeting native protein ligands. In this dissertation, I will present the first …
of stable proteins targeting native protein ligands. In this dissertation, I will present the first …